Drug interactions in the management of HIV infection: an update (Q37000733)

17 August 2017

1 reference

title

Drug interactions in the management of HIV infection: an update (English)

1 reference

17 August 2017

0 references

Sarah M Robertson

1

1 reference

17 August 2017

Scott R Penzak

series ordinal

2

1 reference

17 August 2017

Alice Pau

series ordinal

3

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

Expert Opinion on Pharmacotherapy

17 August 2017

published in

1 reference

17 August 2017

volume

8

1 reference

17 August 2017

issue

17

1 reference

17 August 2017

page(s)

2947-2963

1 reference

Drug interactions in the management of HIV infection

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Drug interactions: Proteins, pumps, and P-450s

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Protein binding in antiretroviral therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Pharmacoenhancement of protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Kaletra (lopinavir/ritonavir).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Transport proteins and intestinal metabolism: P-glycoprotein and cytochrome P4503A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Transport of HIV protease inhibitors through the blood-brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Drug-drug interactions involving membrane transporters in the human kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Role of P-glycoprotein in pharmacokinetics: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Potentially Significant Drug Interactions of Class III Antiarrhythmic Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Pharmacokinetic interactions between HIV antiretroviral therapy and drugs used to treat opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Tacrolimus and lopinavir/ritonavir interaction in liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Mycophenolate mofetil in solid-organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Rifampin and rifabutin drug interactions: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Carbamazepine--indinavir interaction causes antiretroviral therapy failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Ritonavir-induced carbamazepine toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Anticonvulsant and antiretroviral interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

A potentially significant interaction between efavirenz and phenytoin: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Reduced valproate plasma levels possible after introduction of efavirenz in a bipolar patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Indinavir concentrations and St John's wort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

The effect of garlic supplements on the pharmacokinetics of saquinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Influence of Goldenseal Root on the Pharmacokinetics of Indinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Coadministration of milk thistle and indinavir in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Probenecid and zidovudine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Severe anemia secondary to a probable drug interaction between zidovudine and valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Nucleoside analogues and mitochondrial toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Didanosine, interferon-alfa, and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

In vivo antagonism with zidovudine plus stavudine combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Effect of high-dose oral ganciclovir on didanosine disposition in human immunodeficiency virus (HIV)-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Role of purine nucleoside phosphorylase in interactions between 2',3'-dideoxyinosine and allopurinol, ganciclovir, or tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Mechanism of active renal tubular efflux of tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

Combining resistance and pharmacology for optimum patient care

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2947

10.1517/14656566.8.17.2947

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference